Figure 5.

Targeting TGF-β signaling in cancer. (A) Various TGFβ signaling inhibitors including neutralizing antibodies, ligand traps, and receptor kinase inhibitors are depicted. (B) The structure of TβRI kinase (gray) with its ATP competitive inhibitor: a 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogue (green) (Accession code:1RW8) [82].